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“In all affairs it’s healthy now and then to hang 
a question mark on the things you have long 
taken for granted.” —Bertrand Russell
Though a disease-centric approach to drug discovery and development has dominated academic and industrial 
biomedical research, it often fails to leverage 
hard-won expertise in chemistry, biology 
and structural biology. Rather, these 
disciplines thrive in the context of protein-
family, target class–focused approaches. 
Despite the prevalence of target class 
science in industrial and some academic 
drug discovery efforts, a set of principles 
underlying this strategy have yet to be 
delineated. We provide a brief historical 
context of successful target class efforts and 
offer insight into important considerations 
in its application to a wider breadth of 
protein families.
The path that a drug discovery program 
follows is often dictated by selection of a 
molecular target, which is typically based on 
disease-focused knowledge. Target selection 
sets in motion the creation of assays often 
intended to support a high-throughput 
screen (HTS) of a diverse chemical library, 
which, if successful, results in a ‘hit-to-lead/
probe’ effort. Only when a high-quality lead/
probe is in hand can the pharmacologic 
relevance of the selected target in cellular 
or animal models of disease begin to be 
assessed. Thus, a target-to-hit-to-lead effort 
can take 2–3 years and consume considerable 
financial investment before the original 
hypothesis can be tested pharmacologically. 
This is a risky endeavor.
Target selection has accordingly been 
written about at length, with a focus on risk 
minimization1. Risk can be categorized 
as ‘validation risk’ (the likelihood that 
modulation of the target will have a favorable 
outcome in patients) or ‘technical risk’ (the 
likelihood that a tolerable molecule that 
modulates the target in patients can be 
discovered). A target class strategy is based 
on the premise that the scientific expertise 
and physical assets developed within a 
protein family will greatly diminish the 
chances for technical failure. In addition to 
accumulating knowledge, the systematic 
evaluation of functionally related proteins 
seeks to reduce technical risk by diversifying 
the target space of ligandable pockets 
while also increasing the potential clinical 
applications, so that failure to validate 
a single target is not fatal to a program. 
This approach enables efficient preclinical 
pharmacologic validity assessment while 
driving innovation by exploring less well-
documented targets with high-quality 
probes. We believe that a target class 
approach to drug discovery can complement 
disease-focused strategies, enhance the role 
of chemical sciences in driving innovation 
and address some of the risks inherent in 
preclinical discovery. The ability of this 
approach to also prospectively address 
inevitable ligand selectivity issues within a 
protein family is another inherent advantage.
Target class selection
Selection of a target class begins with 
evaluation of a family of structurally and/
or functionally related proteins that have 
been broadly characterized for their 
biological significance. Ideally, the proteins 
in the family would be amenable to high-
resolution structural studies, and an extant 
set of structural data for at least some 
family members would reveal opportunities 
for small-molecule intervention. For 
example, when initiating our chemical 
biology program 9 years ago, we evaluated 
the methyllysine (Kme) reader proteins 
as a potential target class2. At that time, 
chromatin regulation was emerging as an 
exciting area of biology with therapeutic 
relevance3. Additionally, Kme readers 
were known to be a large (>200 members), 
structurally characterized target class with 
a conserved functional recognition motif, 
and yet no ligand discovery efforts had been 
published. While evidence that some Kme 
readers had specific disease implications 
was emerging 4, others remained largely 
unexplored. The major hurdle envisioned 
for success in this target class was the ability 
to design or discover high-affinity, selective 
ligands with sufficient cellular activity to 
use in target validation studies. As this 
hurdle was within our skill set to address, 
Kme readers were chosen as the target class 
for our program. The success in ligand 
discovery for the bromodomain target class 
of acetyllysine readers, which followed 
soon after, also validated our selection of 
a protein–protein interaction module to 
influence chromatin regulation5. Here we 
use Kme readers, along with the archetypical 
target classes of kinases6, G-protein-coupled 
receptors (GPCRs)7 and nuclear receptors 
(NRs)8, to illustrate the history and proven 
advantages of this scientific strategy. Though 
not discussed here, ion channels9 have seen 
similar successes in the application of target 
class approaches to ligand discovery.
Though Kme readers fall broadly 
within the category of epigenetic targets, 
it is important to specify that ‘epigenetic 
proteins’ is not a designation for a target 
class. Specifically, proteins within a target 
class are interrelated via structural or 
functional similarities from a mechanistic 
and chemical viewpoint. For instance, within 
the writers of the epigenetic code, histone 
methyltransferases (HMTs) share some 
similarities in mechanism of action and 
substrates with histone acetyltransferases 
(HATs), but HMTs and HATs are not 
members of the same target class. Crossover 
between the chemical space of the cofactors 
(S-adenosylmethionine and acetyl-CoA for 
HMTs and HATs, respectively) is limited, 
and the substrate recognition sites are very 
different, even though they both recognize 
lysine. Accordingly, the regions of chemical 
space likely to yield specific HMT ligands 
should be more enriched for hits versus other 
HMTs than for HATs.
Building a target class platform
Though different protein classes require 
domain-specific considerations, a set of 
defined practices form the basis of a target 
class approach. Among these, chemical 
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strategies, in vitro assay development and 
structural studies should be given particular 
consideration during the early discovery 
stage (Fig. 1), whereas cellular studies and 
complex mechanism of action (MOA) 
considerations become critical as high-
quality in vitro ligands emerge.
Generation of focused libraries. A 
prerequisite for the optimization of a drug 
or chemical probe is a synthetically tractable 
ligand or ‘hit’. Many successful discovery 
campaigns have relied on HTS of large, 
diverse, small-molecule libraries for the 
discovery of such a starting point. This is an 
expensive endeavor, as the creation, curation 
and growth of such a screening collection 
requires staff and resources supported by a 
long-term funding mechanism10. In contrast, 
a focused compound screening approach 
can be more practical, cost efficient and 
information rich, and is an attractive option 
for hit discovery within a specific target class. 
Emerging platforms in chemical biology 
seek to reduce the investment required 
for diversity-based hit discovery, and we 
consider these to be very promising for 
target class exploitation (Box 1). If resources 
are available, HTS efforts can generate 
unanticipated ligands and binding modes 
that can then enrich focused screening sets.
For emerging target classes, focused 
library design may begin by considering the 
overarching chemical connectivity as defined 
by the structural similarity of the native 
ligand(s), cofactor(s) or substrate(s) and the 
concordant recognition elements within 
each target’s binding sites. For example, 
in the construction of our Kme reader–
biased compound set, we began by making 
compounds containing secondary, tertiary 
and quaternary amines attached to peptidic 
and small-molecule scaffolds to recapitulate 
the interactions of methylated lysine11. In 
the case of enzymes, this practice can be 
expanded to exploit the known geometry 
and catalytic mechanism of the active site. As 
conserved ligand recognition motifs among 
target class members are likely to recognize 
related chemical features, this increases the 
potential for discovering chemical entities 
that interact with several members of the 
target class. Though the design and creation 
of such focused libraries requires an initial 
knowledge base, chemistry resources and 
a substantial upfront time investment, they 
serve as an invaluable, enduring asset for 
target class hit discovery and are meant to 
evolve and grow over time as knowledge of 
the druggable features of the proteins and 
compound binding modes comes to light.
When a target class that has been well 
studied is being considered, the use of 
privileged scaffolds has emerged as a means 
to discover synthetically tractable starting 
points (Fig. 2). Privileged scaffolds comprise 
a core structure that has been characterized 
as having activity against one or more targets 
within a class. These scaffolds theoretically 
enable rapid diversification via rational 
modification to generate libraries that are 
likely to yield novel inhibitors with potential 
for improved potency as well as unique 
selectivity profiles.
Taking the kinase target class as an 
example, early hit-discovery efforts 
via diversity screening revealed a set of 
privileged ATP competitive scaffolds that 
interact with the critical ‘hinge-region’ via 
1–2 hydrogen bonds. Subsequently, the 
different ‘nooks and crannies’ of the ATP 
binding site, which are not highly conserved 
among family members, were successfully 
exploited to improve potency and 
selectivity12. Over a 20-year period, medicinal 
chemistry efforts have resulted in more 
than 30 FDA-approved kinase inhibitors, 
and advances in structural studies and assay 
formats has led to both selective covalent 
and non-ATP competitive inhibitors13. 
Protein kinases are therefore fully enabled 
for rapid ligand discovery and target 
validation efforts, with many unexplored 
targets remaining. By comparison, the 
GPCR superfamily recognizes a diverse set 
of endogenous ligands and might be better 
described as subfamilies of GPCRs from a 
ligand recognition perspective. Targeting 
GPCRs with known ligands can follow a 
biased library design or privileged scaffold 
approach, whereas pursuing orphan GPCRs 
poses a distinct challenge. In this case, library 
construction and screening must instead 
focus on chemical diversity and a HTS, 
which, if successful, can create knowledge 
and opportunities for focused libraries 
targeting an unexplored GPCR subfamily.
Assembly of an appropriate assay platform. 
The selection of a representative protein 
panel and assay format is essential for a 
successful target class campaign and is 
the critical first step in building an assay 
platform. As many target classes are too 
large to allow comprehensive screening of all 
members, the selection of a representative 
panel of proteins from the target class 
should consider both highly homologous 
targets, to explore ligand selectivity at an 
early stage, and structurally distinct but 
Figure 1 | The three principles of target class discovery. The purposeful design and construction of 
focused compound libraries based on structural and ligand similarities, often guided by available 
structural information, can effectively enable target class hit discovery when coupled with robust 
assay platforms that allow extensive cross-screening against a carefully chosen panel of representative 
proteins. Ultimately, a target class platform composed of these three interconnected principles will 
deliver high-quality ligands in a rational, systematic, and productive fashion with diminished chances for 
technical failure.
Box 1 | Leveraging target class approaches in chemical biology. 
Target class science combines naturally with modern approaches in hit discovery and chemical biology. 
For example, in our Kme reader work, we recently demonstrated that focused library generation via one-
bead-one-compound approaches is amenable to target class ligand discovery, selectivity optimization 
and screening23, but additional combinatorial approaches including DNA display technologies, other 
in vitro display platforms (phage and mRNA), and dynamic combinatorial chemistry would benefit from 
a target class focus. Target class strategies provide a means for rigorous identification of selective hits 
within these diverse libraries. Additionally, activity-based protein profiling (ABPP) has been applied to 
target discovery, whereby a reactive probe differentially captures the active site of a class of enzymes 
in normal and diseased cells24. These differential activities may lead to new strategies for combination 
therapies (or designed polypharmacology) and identify new molecular targets. Lastly, the emerging 
power of proteomics combined with thermal profiling presents an unbiased approach to cellular 
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functionally similar domains with an eye 
toward inclusion of binding site diversity. 
The curse of a medicinal chemist is to be 
‘almost right’ with a ligand hypothesis and 
miss a potentially good starting point. By 
screening multiple targets with a conserved 
recognition motif, being ‘almost right’, and 
inactive for one target, can lead to a potent 
ligand for another member of the class. Thus, 
diverse ligand hypotheses are assessed versus 
a set of related targets. Although a screening 
panel can initially be chosen on the basis of 
a rational set of criteria, it should be fluid to 
accommodate new targets as novel biology 
is revealed and traction is made with specific 
family members within the target class. As 
targets in the class are advanced through 
the hit-to-lead process, new analogs would 
continue to be cross-screened for selectivity 
and creation of target class structure–activity 
relationships (SAR)14.
Following the design of a diverse protein 
panel, an effective primary in vitro assay 
should allow extensive cross-screening of 
focused compound collections to enable 
hit discovery and SAR development. 
Ideally, the chosen assay should be robust, 
adaptable to most proteins within the target 
class, cost effective, and should generate 
limited false positive hits. The concurrent 
use of a counterscreen assay, wherein a 
key component of the assay (such as the 
target protein) is eliminated, can serve 
as an effective means to quickly identify 
compounds interfering with the assay that 
would otherwise appear as hits. In vitro 
assays that have been commonly employed 
for target class screening include binding, 
competition and enzymatic activity assays, 
although for some targets (GPCR’s, ion 
channels, and NRs), a cellular assay is the 
most appropriate screening method for hit 
discovery. Orthogonal, secondary assays such 
as isothermal titration calorimetry (ITC) 
are essential for confirming preliminary 
hits before initiating follow-up chemistry. If 
sufficiently potent, ligands should progress 
to cellular studies that explore direct target 
engagement, cell permeability (when 
applicable) and functional effects of the 
compound.
Cellular assessment of ligand potency, 
selectivity and MOA is a rapidly developing 
area and may become a primary source 
of hit generation and characterization for 
some target classes15,16. Deconvoluting 
on-target from off-target effects in cells 
requires complementary genetic techniques 
such as engineered assays, knockouts and 
inactivating mutations17. Importantly, 
these techniques often do not yield a clear 
confirmation that the observed biological 
effects are the result of disruption of the 
desired target, and, in these instances, target-
specific biology may be distinguished via 
pharmacology using a structurally distinct 
ligand with target affinity, but a unique 
selectivity profile. The cell is the vessel 
wherein target class strategies and biological 
knowledge must be integrated to advance a 
project toward translation, and this can be 
a challenging area for less explored target 
classes. In our experience with Kme readers, 
collaboration with chromatin biology labs in 
which the appropriate assays and expertise 
exist for cellular MOA studies is critical.
In the case of GPCRs, for example, 
numerous factors must be accounted for in 
the selection of appropriate cellular assays. 
Though they are efficient, binding assays 
do not necessarily select compounds that 
elicit a functional outcome, but functional 
assays may require substantial upfront 
investigation and resources to discover 
the appropriate biological readout for 
the many orphan receptors of this class18. 
Additionally, GPCRs signal through multiple 
pathways and therefore require not only 
characterization of target selectivity but also 
functional selectivity19. Fortunately, decades 
of work within this target class has enabled 
sophisticated assays that anticipate these 
issues.
Final characterization of a chemical 
probe should include extensive profiling 
against protein target families, both related 
and unrelated to the primary target, so 
that compound effects observed in cellular 
assays can be attributed to the inhibition 
of the known target(s). A variety of assay 
systems and technologies have been 
developed to comprehensively interrogate 
compounds against various protein 
families. In our own work in collaboration 
with the Bedford lab2 targeting Kme 
readers, protein microarrays have enabled 
rapid, qualitative profiling of biotin labeled 
ligands. Over a hundred reader proteins 
spanning more than six domain types are 
available for profiling via a chromatin-
associated domain array (CADOR) chip20. 
For many established protein classes 
such as GPCR’s, kinases, NRs and even 
bromodomains, there are commercially 
available assays to enable broad compound 
profiling.
Construction of a structural-knowledge 
foundation. Advances in structural 
biology have substantially expanded 
our understanding of ligand–protein 
interactions, and techniques including 
X-ray crystallography, 2D and 3D NMR 
and cryo-electron microscopy have 
revolutionized the strategies that can be 
employed to discover new ligands for 
protein targets. Additionally, the use of 
homology models for proteins that lack 
structural information provides fodder 
for ligand hypotheses in the absence of 
a resolved structure. Structure-based 
design spurs the creation and expansion of 
focused compound libraries to elaborate 
on target class SAR and increase the 
odds for technical success. Plexxikon’s 
application of scaffold hopping represents 
an exceptional example of the crosstalk 
between biochemical screening and 
structural biology in target class research, 
whereby a preliminary hit against one 
kinase led to the development of a drug 
for a wholly different kinase (Fig. 2)21. 
Ultimately, a structural-knowledge base 
provides invaluable information on 
routes to designed polypharmacology or, 
conversely, selectivity that may otherwise be 
overlooked, especially in the early stages of 
ligand optimization.
The target class payoff
Tackling an unprecedented target class 
requires long-term focus and perseverance, 
as knowledge grows slowly in the 











Figure 2 | Overview of target class scaffold hopping and optimization. Evaluating proteins that are 
connected by their structural similarities or functional redundancies enables diverse ligand hypotheses to 
be tested against a set of related targets. Such ligand hypotheses can be the result of structure- or ligand-
based design efforts. Alternatively, privileged scaffolds, which are known to have activity against one or 
more targets within the class, may be available and can serve as the basis for creating focused compound 
libraries that are likely to yield ligands of novel potencies and selectivity profiles. Screening a carefully 
chosen panel of related targets can also facilitate scaffold hopping when a hit for one target is shown to 
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sets, assay platforms and structural data 
and systems) and intellectual assets 
eventually accumulate, making the 
process far more efficient and increasing 
the quality of the hypotheses and results. 
This is demonstrably true for the kinase 
target class, as over the last 20 years 
industry and academics have built a well-
established platform and knowledge base 
that enables efficient prosecution of any 
new kinase target12; however, this effort was 
initially not purposeful, and the physical 
assets remain inaccessible to many. With 
emerging target classes, an intentional 
effort to create accessible platforms and 
share learnings and expertise would greatly 
accelerate biomedical science aimed at 
new medicines. Our modest success in the 
Kme reader class required talented and 
supportive collaborators in the Structural 
Genomics Consortium and at other 
academic institutions.
Unfortunately, the single-target, 
disease-focused paradigm continues 
to dominate biomedical research. This 
frequently contributes to the production 
of low-quality, nonreproducible results, 
because each target is most often a stand-
alone effort without the assay expertise, 
chemical tools, cellular target engagement 
knowledge16 and rigor that can emerge 
from target class–focused science22. 
Though ‘known unknowns’ and ‘unknown 
unknowns’ are risks in all areas of drug 
discovery, they are huge pitfalls in tackling 
one-off targets: unknown selectivity issues, 
unknown SAR for homologous targets, 
unknown MOAs within the cell, among 
others. Fortunately, unknowns are likely 
to be exposed over time in a well-explored 
target class, for example, the capacity 
for ligands to demonstrate functional 
selectivity in GPCRs and how to design 
selective ligands for kinases.
Target class science has led directly 
to new biologic understanding driven 
by ligand discovery. For example, in the 
NR area, GlaxoSmithKline scientists 
deorphanized a number of targets, and 
this led to new insights into members of 
the family that bind with low affinity to 
highly abundant cellular molecules such 
as fatty acids and oxysterols8. Likewise, the 
regulatory function of the NR pregnane 
X receptor (PXR) was uncovered through 
realization of the bridge it provides between 
small molecules and p450 induction. The 
target class is the best organizing paradigm 
and intellectual home for experimental 
design, technology development, data 
analysis and interpretation in the early 
stages of drug discovery and needs to be 
understood, embraced and cultivated by 
the biomedical community. The synergies 
between this strategy and disease-oriented 
research readily emerge once high-quality 
leads and probes demonstrate compelling 
outcomes in preclinical models.
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